Sunshine Biopharma, Inc. (OTCBB: SBFM), which has designed and synthesized a new compound, Adva-27a, that acts as an inhibitor of multidrug resistant breast cancer cells in vitro, today announced that it will be presenting new scientific data at the American Association for Cancer Research Meeting March 31-April 4, 2012, in Chicago, Illinois, together with its research collaborator, Binghamton University, a State University of New York.

According to the American Cancer Society, approximately 1.5 million new cases of cancer are diagnosed each year in the U.S. Of these, over 230,000 are new breast cancer cases. The American Cancer Society also reports that there are over 11 million Americans living with cancer. Of these, 2.5 million are breast cancer patients. Virtually all cancers types are either aggressive at the onset or become aggressive or multidrug resistant over time. Currently, there are little or no treatment options available for multidrug resistant breast cancer patients.

The data concerning Adva-27a, which will be presented at the Chicago meeting by the Company’s research collaborator, Dr. Susannah Gal of Binghamton University, show that Adva-27a efficiently kills multidrug resistant breast cancer cells in vitro. “If the activity of Adva-27a proves to be as remarkable in vivo, this new compound would represent a breakthrough for breast cancer patients,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma.